1065175-72-5

Upstream product

• 98-80-6 phenylboronic acid 
• 197460-40-5 1-(1,1-dimethylethyl) 7-methyl 2,3-dihydro-1H-indole-1,7-dicarboxylate 
• 1065181-76-1 1-(1,1-dimethylethyl) 7-methyl 5-bromo-3-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1H-indole-1,7-dicarboxylate 
• 1065181-75-0 1-(1,1-dimethylethyl) 7-methyl 5-bromo-3-(tetrahydro-2H-thiopyran-4-yl)-1H-indole-1,7-dicarboxylate 
• 1065181-72-7 methyl 5-bromo-3-(tetrahydro-2H-thiopyran-4-yl)-1H-indole-7-carboxylate 
• 860624-90-4 5-bromo-1H-indole-7-carboxylic acid 
• 860624-89-1 methyl 5-bromo-1H-indole-7-carboxylate 
• 860624-87-9 1-(1,1-dimethylethyl) 7-methyl 5-bromo-2,3-dihydro-1H-indole-1,7-dicarboxylate 
• 860624-88-0 methyl 5-bromo-2,3-dihydro-1H-indole-7-carboxylate 
• 1065181-52-3 1-(1,1-dimethylethyl) 7-ethyl 2,3-dihydro-1H-indole-1,7-dicarboxylate 
• 1065181-79-4 5-bromo-3-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1H-indole-7-carboxylic acid 
• 1065181-70-5 1-(1,1-dimethylethyl) 7-ethyl 5-bromo-3-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1H-indole-1,7-dicarboxylate 
• 1065181-68-1 1-(1,1-dimethylethyl) 7-ethyl 5-bromo-3-(tetrahydro-2H-thiopyran-4-yl)-1H-indole-1,7-dicarboxylate 
• 1065181-66-9 ethyl 5-bromo-3-(tetrahydro-2H-thiopyran-4-yl)-1H-indole-7-carboxylate 

Relevant academic research and scientific papers

3,5-Disubstituted-indole-7-carboxamides as IKKβ Inhibitors: Optimization of Oral Activity via the C3 Substituent

IκB kinase β (IKKβ or IKK2) is a key regulator of nuclear factor kappa B (NF-κB) and has received attention as a therapeutic target. Herein we report on the optimization of a series of 3,5-disubstituted-indole-7-carboxamides for oral activity. In doing so

INDOLE CARBOXAMIDES AS IKK2 INHIBITORS

The invention is directed to novel indole carboxamide compounds. Specifically, the invention is directed to compounds according to formula (I): wherein R1, R2, R3, R4, and m are as defined herein. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, rhinitis, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.